Premium
CDK5RAP2 gene and tau pathophysiology in late‐onset sporadic Alzheimer's disease
Author(s) -
Miron Justin,
Picard Cynthia,
Nilsson Nathalie,
Frappier Josée,
Dea Doris,
Théroux Louise,
Poirier Judes
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.12.004
Subject(s) - disease , single nucleotide polymorphism , biology , genetic association , genetics , gene , alzheimer's disease , allele , genome wide association study , genetic variation , population , medicine , genotype , environmental health
Because currently known Alzheimer's disease (AD) single‐nucleotide polymorphisms only account for a small fraction of the genetic variance in this disease, there is a need to identify new variants associated with AD. Methods Our team performed a genome‐wide association study in the Quebec Founder Population isolate to identify novel protective or risk genetic factors for late‐onset sporadic AD and examined the impact of these variants on gene expression and AD pathology. Results The rs10984186 variant is associated with an increased risk of developing AD and with a higher CDK5RAP2 mRNA prevalence in the hippocampus. On the other hand, the rs4837766 variant, which is among the best cis‐expression quantitative trait loci in the CDK5RAP2 gene, is associated with lower mild cognitive impairment/AD risk and conversion rate. Discussion The rs10984186 risk and rs4837766 protective polymorphic variants of the CDK5RAP2 gene might act as potent genetic modifiers for AD risk and/or conversion by modulating the expression of this gene.